William Chou, M.D. has served as our Chief Executive Officer and member of our Board of Directors since October 2022. Dr. Chou is an accomplished executive with nearly 20 years of healthcare experience across a range of development and commercialization roles. Dr. Chou previously served as CEO of Aruvant Sciences (Aruvant), a clinical-stage biopharmaceutical company focused on developing gene therapies for rare disease, from November 2019 to October 2022. Prior to joining Aruvant, from May 2008 to October 2019, Dr. Chou served in a variety of leadership roles at Novartis Pharma AG (Novartis), including Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy where he oversaw the global commercial launch of Kymriah®, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah® lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an MBA from the Yale School of Management, an MD from the University of Pittsburgh School of Medicine, and an AB in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

Sue Browne, Ph.D., is SVP of Research and Development. Since joining Passage Bio in June 2021 she has served as our VP of Biology and Head of Biomarkers and Precision Medicine. Dr. Browne has extensive experience in drug discovery and development for neurological disorders, with particular focus on neurodegenerative, neuropsychiatric, and rare diseases. Prior to joining Passage, Dr. Browne was an Executive Director at Acadia Pharmaceuticals from January 2019 until May 2021, where she was responsible for strategic expansion of the CNS drug development pipeline as part of the Translational Research and External Innovation group. Dr. Browne also spent 5 years as Director of Small Molecule Discovery Research at Teva Pharmaceuticals, and seven years in the Department of Neuroscience at Merck Research Laboratories. Dr. Browne’s industry career is built upon an academic foundation researching the etiologies of neurodegenerative disorders including Huntington’s disease, ALS, and Parkinson’s disease. From 1999 to 2006 she served as an Assistant Professor in the Neuroscience Program Faculty and Department of Neurology at Cornell University’s Weill Graduate School of Medical Science, following post-graduate research in the Neurology Department at Massachusetts General Hospital. She has been a member of the Scientific Advisory Board for the Huntington’s Disease Society of America since 2015. Dr. Browne received her Ph.D. in Neuropharmacology from the University of Glasgow, and her B.Sc. in Pharmacology from the University of Aberdeen in Scotland.

Edgar B. (Chip) Cale has served as our General Counsel since September 2019 and Corporate Secretary since December 2019. From June to October 2022, Mr. Cale also served as our interim Chief Executive Officer. From June 1998 to July 2019, Mr. Cale served in various senior leadership roles at GlaxoSmithKline plc, a multinational pharmaceutical company, most recently as Senior Vice President, Legal Corporate Functions. Prior to this, Mr. Cale also served as Vice President, and head of legal support for GSK’s worldwide business development, and Vice President, General Counsel of GSK Vaccines. Prior to that, Mr. Cale served as a corporate and securities lawyer supporting emerging growth companies in the life science and technology industries at Venture Law Group LLP and Brobeck, Phleger & Harrison LLP. Mr. Cale received a B.A. in Biology from the University of Pennsylvania and a J.D. from the University of California, Berkeley.

James M. Wilson, MD, PhD, is the Director of the Gene Therapy Program; Rose H. Weiss Professor and Director of the Orphan Disease Center and Professor of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wilson serves as Chief Scientific Advisor at Passage Bio. Dr. Wilson’s laboratory has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published over 550 papers and is named on over 110 patents. After launching his faculty career in the Howard Hughes Medical Institute at the University of Michigan, he moved to the University of Pennsylvania in 1993. Dr. Wilson completed his training in Internal Medicine at the Massachusetts General Hospital followed by a postdoctoral fellowship at the Whitehead Institute, where he began his work in gene therapy.

Maxine Gowen, Ph.D. has served as a member of our Board of Directors since February 2021, and as Chairperson of the Board of Directors since September 2021. Dr. Gowen currently serves on the boards of directors for Merus N.V. and Aclaris Therapeutics, Inc., each a public biotechnology company. Prior to that, Dr. Gowen served as Chief Executive Officer of Tamuro Bio from July 2019 to December 2021, and as the founding President and Chief Executive Officer of Trevena, Inc., from 2007 to October 2018, where she served as a member of Trevena’s board of directors from 2008 to 2021. Dr. Gowen previously held a variety of leadership roles at GlaxoSmithKline over a period of 15 years. Additionally, Dr. Gowen served on the board of Akebia Therapeutics, Inc from 2014 to 2021, the board of Idera Pharmaceuticals from 2016 to 2022, the board of directors and executive committee of BIO, an industry association, from 2008 to 2018, and the board of directors and executive committee of Life Sciences Pennsylvania, an industry association from 2016 to 2021. Dr. Gowen received a B.Sc. in biochemistry from the University of Bristol, U.K., a Ph.D. in cell biology from the University of Sheffield, U.K., and an M.B.A. from the Wharton School of the University of Pennsylvania.

William Chou, M.D. has served as our Chief Executive Officer and member of our Board of Directors since October 2022. Dr. Chou is an accomplished executive with nearly 20 years of healthcare experience across a range of development and commercialization roles. Dr. Chou previously served as CEO of Aruvant Sciences (Aruvant), a clinical-stage biopharmaceutical company focused on developing gene therapies for rare disease, from November 2019 to October 2022. Prior to joining Aruvant, from May 2008 to October 2019, Dr. Chou served in a variety of leadership roles at Novartis Pharma AG (Novartis), including Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy where he oversaw the global commercial launch of Kymriah®, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah® lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an MBA from the Yale School of Management, an MD from the University of Pittsburgh School of Medicine, and an AB in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

Athena Countouriotis, M.D. has served as a member of our Board of Directors since February 2020. Dr. Countouriotis has served as Chief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics, a private oncology therapeutics company, since October 2022. Dr. Countouriotis currently serves on the board of directors of BioMarin Pharmaceutical Inc., a public pharmaceutical company, Iovance Biotherapeutics, Inc., a public oncology therapeutics company, Recludix Therapeutics, Inc., a private oncology therapeutics company, Leal Therapeutics, Inc., a private central nervous system diseases company, and Capstan Therapeutics, Inc, a private cell therapy company. Dr. Countouriotis served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. from September 2018 to August 2022, and as Chief Medical Officer of Turning Point Therapeutics from May 2018 to September 2018. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018, and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit’s acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. In addition, Dr. Countouriotis previously served on the board of directors of Cardiff Oncology, a public oncology therapeutics company. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. Dr. Countouriotis received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.

Derrell D. Porter, M.D. has served as member of our Board of Directors since May 2021. Dr. Porter has served as Chief Executive Officer and as member of the board of directors of cTRL Therapeutics, Inc., a private company, since November 2023. Dr. Porter has served on the board of directors of Acumen Pharma, a public company, since January 2023, and also serves on the boards of directors of several private companies. Previously, Dr. Porter served as Founder and Chief Executive Officer at Cellevolve Bio, Inc., a privately held biotechnology company from March 2020 to November 2023. Prior to that, Dr. Porter served as SVP and Head of Commercial at Atara Biotherapeutics, Inc. from May 2017 to October 2019. Prior to joining Atara, Dr. Porter served as a Vice President with Gilead Sciences from April 2013 to May 2017, where he was responsible for corporate strategy, commercial planning, and global launch preparation for all of Gilead’s therapeutic areas. Previously, Dr. Porter was at AbbVie and Amgen, where he served in multiple US, EU and global roles of increasing responsibility in strategy, corporate development, business unit management, and sales & marketing. Dr. Porter began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. Dr. Porter holds an M.D. from the University of Pennsylvania, where he was a Twenty First Century Scholar, an M.B.A. from The Wharton School and a Bachelor’s degree in neuroscience from the University of California Los Angeles.

Dolan Sondhi, Ph.D. has served as a member of our Board of Directors since July 2023. Dr. Sondhi currently serves as a Professor of Research in Genetic Medicine at Weill Cornell Medical College, a position she has held since November 2015. Dr. Sondhi also holds a number of appointments at Weill Cornell Medical College, including as an Elected Member of the Weill Cornell Medicine Mentoring Academy since June 2020, an Associate Director of the Belfer Gene Therapy Core Facility since September 2012, and Product Manager for all Neurological Gene Therapy Projects for the Department of Genetic Medicine since January 2000. In addition, Dr. Sondhi has served as a council member for the Gerson Lehrman Group, a financial and global information services company, and as an advisor to Guidepoint, an expert network, since January 2018. Dr. Sondhi holds a Ph.D. in Chemistry from Brown University and a B.S. with Honors in Chemistry from St. Stephens College of Delhi University. Dr. Sondhi completed her post-doctoral fellowship in Bioorganic Chemistry at Rockefeller University.

Sandip Kapadia has served as a member of our Board of Directors since December 2019. Mr. Kapadia has served as the Chief Financial Officer of Harmony Biosciences Holdings, Inc., a public biopharmaceutical company, since March 2021. Mr. Kapadia has served on the board of directors of Molecular Partners AG, a public company, since April 2020. Mr. Kapadia previously served as the Chief Financial Officer for Intercept Pharmaceuticals, Inc. from July 2016 to March 2021. Prior to that, Mr. Kapadia served in various leadership capacities within finance over 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the U.S. Mr. Kapadia previously served on the board of directors of VectivBio AG from October 2020 to July 2023. Mr. Kapadia received a B.S. in Accounting from Montclair State University and an M.B.A. from Rutgers University, and is also a U.S. Certified Public Accountant.

Tom Kassberg has served as a member of our Board of Directors since September 2024.  Mr. Kassberg has served as Chief Business Officer of Ultragenyx Pharmaceutical Inc. since November 2011. Mr. Kassberg previously worked at Proteolix, Inc., where he served as Executive Vice President of Corporate Development, overseeing business development, strategic planning and legal affairs. Prior to Proteolix, he served as Senior Vice President of Corporate Development and Commercial Operations at InterMune, Inc. Mr. Kassberg was a co-founder of Plexxikon, where he served as Vice President, Business and Corporate Development. Prior to Plexxikon, he served as Senior Director of Business Development and Corporate Licensing at SUGEN until the company’s acquisition by Pharmacia. Mr. Kassberg began his career at Bristol Myers Squibb where he held a variety of positions in strategic planning, managed care sales, and financial and product analysis. He earned a B.A. in economics and management from Gustavus Adolphus College and an M.B.A. from Northwestern University’s Kellogg School of Management.

Saqib Islam has served as a member of our Board of Directors since March 2019. Mr. Islam has served as Chief Executive Officer and a member of the board of directors of SpringWorks Therapeutics, Inc., a public biopharmaceutical company, since August 2018, and from August 2017 to August 2018, he served as Chief Financial Officer and Chief Business Officer of SpringWorks Therapeutics. Mr. Islam has also served on the board of directors for ARS Pharmaceuticals, Inc., a public biopharmaceutical company, since July 2017. From February 2016 to August 2017, Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc., a biotechnology company. From February 2013 to February 2016, Mr. Islam served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc., a pharmaceutical company. Prior to joining Alexion, Mr. Islam worked for more than 25 years in international business management with a focus on business development, strategic decision-making and planning and capital markets, previously holding managing director positions at Morgan Stanley and Credit Suisse. Mr. Islam currently serves on the board of directors of ARS Pharmaceuticals, Inc., a publicly traded biotechnology company. Mr. Islam received a B.A. in Communications from McGill University and a J.D. from Columbia Law School.